Maternal Fetal Medicine
Tajossadat Allameh; Zahra Allameh; Zahra Javanmardi; Elham Moazam; Maryam Dehghan
Volume 8, Issue 2 , March and April 2023, , Pages 131-136
Abstract
Background & Objective: Due to the uncertainties of maternal and neonatal complications after delivery and the lack of similar studies in this regard, this study aimed to compare the maternal and fetal complications of vaginal birth after C-Section (VBAC), natural delivery and repeat Cesarean ...
Read More
Background & Objective: Due to the uncertainties of maternal and neonatal complications after delivery and the lack of similar studies in this regard, this study aimed to compare the maternal and fetal complications of vaginal birth after C-Section (VBAC), natural delivery and repeat Cesarean section in Isfahan province.Materials & Methods: In this one-year descriptive cross-sectional study, 49889 pregnant women who had the natural childbirth (29631 deliveries), elective repeat Cesarean section (20148 deliveries) and VBAC delivery (110 deliveries) were enrolled, then maternal and neonatal complications were compared in three groups.Results: There was a significant difference between the three groups based on the maternal and neonatal outcome, Apgar scores in the first and fifth minutes after delivery and the need for resuscitation at birth (P <0.05). Neonatal outcome was better in natural delivery and then VBAC compared to repeat C-section, respectively. Maternal outcome was better in VBAC and then repeat C-section than the natural childbirth. Apgar scores in the first and fifth minute were better in VBAC, and later natural delivery than repeat C-section. Resuscitation at birth demonstrated better results for natural delivery and then VBAC than repeat C-section.Conclusion: Utilizing VBAC and natural delivery have better maternal and fetal outcomes compared to C-section, along with being more satisfactory and safer.
Reproductive Medicine
Shahrzad Zademodares; Masoumeh Abbaspour; Maryam Anbarluei; Nayereh Rahmati; Marzieh Fathi; Zahra Naeiji
Volume 6, Issue 4 , August 2021, , Pages 161-166
Abstract
Background & Objective: This retrospective study aims to evaluate the impact of pre-gestational maternal age and body weight on the outcome of IVF in women with polycystic ovary syndrome (PCOS). Materials & Methods: Medical records of 200 known cases of PCOS treated in a third level ...
Read More
Background & Objective: This retrospective study aims to evaluate the impact of pre-gestational maternal age and body weight on the outcome of IVF in women with polycystic ovary syndrome (PCOS). Materials & Methods: Medical records of 200 known cases of PCOS treated in a third level referral center by the same therapeutic protocol were evaluated retrospectively. Demographic data, maternal body mass index (BMI), hormonal profile (LH, FSH, estradiol, and anti-mullerian), IVF cycle parameters and outcomes were documented. Patients were categorized into three groups based on their BMI (normal=18.5-24.9, overweight=25-30, obese≥30). IVF cycle parameters and outcomes were compared in the three groups. Effect of age was also evaluated by comparing the results in patients aged <35 and ≥35.Results: Mean age of patients was 32.5 (±5.2). A number of 72 patients had normal BMI, 85 patients were overweighed and 43 cases were obese. Baseline hormonal profile was similar in the three groups. Total dose of administered FSH was similar in the three groups. Number of retrieved oocytes was significantly higher in patients with BMI>30 but the number of mature oocytes and number of embryos were statistically lower in this group. Size of follicles showed no statistically significant difference in the three groups. Clinical pregnancy rate was significantly lower in patients with BMI>30 kg/m2 and age>35 years old.Conclusion: BMI>30 and age>35 years old have a statistically significant negative impact on IVF success rate.
Shirin Haghighat
Volume 4, Issue 4 , September and October 2019, , Pages 131-134
Abstract
Epithelial ovarian cancer is one of the most common gynecological malignancies worldwide with an incidence of 225000 cases annually. For most patients, multimodality treatment including cytoreductive surgery and combination chemotherapy is an accepted standard of care. Despite the relatively favorable ...
Read More
Epithelial ovarian cancer is one of the most common gynecological malignancies worldwide with an incidence of 225000 cases annually. For most patients, multimodality treatment including cytoreductive surgery and combination chemotherapy is an accepted standard of care. Despite the relatively favorable response to initial treatment, relapse free survival and overall survival are disappointing in patients with advanced ovarian cancer. Therefore, new treatment approaches have been proposed in recent years. The present review aims to describe the most relevant data published during the last four years on new approach to advanced ovarian cancer. Therefore, relevant studies were searched through Pubmed, Cochrane library and Scopus database published online until 2019. The most important changes studied in recent years have included the addition of new chemotherapy or targeted agent to first-line chemotherapy. Although combination of intravenous paclitaxel and carboplatin is currently accepted as the standard of care for treatment of advanced ovarian cancer, discussion around the intraperitoneal chemotherapy is still an important challenge. Additionally, much efforts have been dedicated to design an appropriate maintenance treatment as a goal of diminish the risk of recurrence. This review summarizes the results of most recent phase 3 trials surrounding optimal first-line chemotherapy, addition of a targeted agent including bevacizumab and maintenance treatment.
Nadereh Behtash; Setareh Akhavan
Volume 4, Issue 3 , September and October 2019, , Pages 120-126
Abstract
Uterine sarcomas (US) are relatively rare malignant tumor of the uterine mesenchymal tumor. The present study evaluated the outcomes of patients with different types of uterine sarcoma in Iranian women during a 5-years survey. During 2014-2019, a case series of twenty-three patients of US (four cases ...
Read More
Uterine sarcomas (US) are relatively rare malignant tumor of the uterine mesenchymal tumor. The present study evaluated the outcomes of patients with different types of uterine sarcoma in Iranian women during a 5-years survey. During 2014-2019, a case series of twenty-three patients of US (four cases of leiomyosarcoma (LMS), nine cases of endometrial stromal sarcoma (ESS), seven cases of carcinosarcoma (CS), and three cases of adenosarcoma (AS)) were studied. One case of AS needed adjuvant radiotherapy and a recurrence was occurred in this case four years later. Two cases of CS have died during study period. All of ESS cases were alive by the study duration. One case who did not receive radio/chemotherapy experienced a bronchial recurrence after 8-years of ESS diagnosis Immunohistochemistry test on tumoral cells of three patients for vimentin+Ki67, BCL2+CD64+Ki67, ER+PR+WT1+Ki67 expressions were 30%, 30%, 15% respectively. Two cases of CS died during the study period. Even with multimodalities of treatment, the prognosis of uterine sarcoma is still poor and early diagnosis seems to improve the prognosis of the patients.
